TY - JOUR
T1 - Structural basis of nSH2 regulation and lipid binding in PI3Ka
AU - Miller, Michelle Susan
AU - Schmidt-Kittler, Oleg
AU - Bolduc, David M
AU - Brower, Evan T
AU - Chaves-Moreira, Daniele
AU - Allaire, Marc
AU - Kinzler, Kenneth W
AU - Jennings, Ian
AU - Thompson, Philip
AU - Cole, Philip A
AU - Amzel, L Mario
AU - Vogelstein, Bert
AU - Gabelli, Sandra B
PY - 2014
Y1 - 2014
N2 - We report two crystal structures of the wild-type phosphatidylinositol 3-kinase a (PI3Ka) heterodimer refined to 2.9 ? and 3.4 ? resolution: the first as the free enzyme, the second in complex with the lipid substrate, diC4-PIP2, respectively. The first structure shows key interactions of the N-terminal SH2 domain (nSH2) and iSH2 with the activation loop that suggest a mechanism by which the enzyme is inhibited in its basal state. In the second structure, the lipid substrate binds in a positively charged pocket adjacent to the ATP-binding site, bordered by the P-loop, the activation loop and the iSH2 domain. An additional lipid-binding site was identified at the interface of the ABD, iSH2 and kinase domains. The ability of PI3Ka to bind an additional PIP2 molecule was confirmed in vitro by fluorescence quenching experiments. The crystal structures reveal key differences in the way the nSH2 domain interacts with wild-type p110a and with the oncogenic mutant p110aH1047R. Increased buried surface area and two unique salt-bridges observed only in the wild-type structure suggest tighter inhibition in the wild-type PI3Ka than in the oncogenic mutant. These differences may be partially responsible for the increased basal lipid kinase activity and increased membrane binding of the oncogenic mutant.
AB - We report two crystal structures of the wild-type phosphatidylinositol 3-kinase a (PI3Ka) heterodimer refined to 2.9 ? and 3.4 ? resolution: the first as the free enzyme, the second in complex with the lipid substrate, diC4-PIP2, respectively. The first structure shows key interactions of the N-terminal SH2 domain (nSH2) and iSH2 with the activation loop that suggest a mechanism by which the enzyme is inhibited in its basal state. In the second structure, the lipid substrate binds in a positively charged pocket adjacent to the ATP-binding site, bordered by the P-loop, the activation loop and the iSH2 domain. An additional lipid-binding site was identified at the interface of the ABD, iSH2 and kinase domains. The ability of PI3Ka to bind an additional PIP2 molecule was confirmed in vitro by fluorescence quenching experiments. The crystal structures reveal key differences in the way the nSH2 domain interacts with wild-type p110a and with the oncogenic mutant p110aH1047R. Increased buried surface area and two unique salt-bridges observed only in the wild-type structure suggest tighter inhibition in the wild-type PI3Ka than in the oncogenic mutant. These differences may be partially responsible for the increased basal lipid kinase activity and increased membrane binding of the oncogenic mutant.
UR - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=2263&path%5B%5D=3755
U2 - 10.1158/1538-7445.AM2014-LB-326
DO - 10.1158/1538-7445.AM2014-LB-326
M3 - Article
VL - 5
SP - 5198
EP - 5208
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 14
ER -